Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1G | O43497 | 2/20 | 0.52 |
| ▸ | CACNA1H | O95180 | 2/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.48 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.48 |
| ▸ | CCR5 | P51681 | 2/20 | 0.46 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.46 |
| ▸ | MTOR | P42345 | 1/20 | 0.46 |
| ▸ | PRKDC | P78527 | 1/20 | 0.46 |
| ▸ | PRKCG | P05129 | 1/20 | 0.45 |
| ▸ | PRKCB | P05771 | 1/20 | 0.45 |
| ▸ | PRKCA | P17252 | 1/20 | 0.45 |
| ▸ | PRKCH | P24723 | 1/20 | 0.45 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.45 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.45 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.44 |
| ▸ | OGFRL1 | Q5TC84 | 1/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7596262 | 0.94 | OPRM1 (0.49) | CACNA1GCACNA1HCYP3A4CYP2D6OPRM1 | |
| SCHEMBL27194852 | 0.89 | CYP3A4 (0.53) | CACNA1GCACNA1HCYP3A4CYP2D6OPRM1 | |
| SCHEMBL8063089 | 0.89 | OPRM1 (0.50) | CACNA1GCACNA1HCYP3A4CYP2D6OPRM1 | |
| SCHEMBL24709345 | 0.88 | CACNA1G (0.66) | CACNA1GCACNA1HCYP3A4CYP2D6OPRM1 | |
| SCHEMBL30849340 | 0.88 | CACNA1G (0.66) | CACNA1GCACNA1HCYP3A4CYP2D6OPRM1 | |
| SCHEMBL24709329 | 0.87 | CACNA1G (0.71) | CACNA1GCACNA1HCYP3A4CYP2D6OPRM1 | |
| SCHEMBL30849341 | 0.87 | CACNA1G (0.71) | CACNA1GCACNA1HCYP3A4CYP2D6OPRM1 | |
| SCHEMBL3098947 | 0.87 | CYP2D6 (0.57) | CACNA1GCACNA1HCYP3A4CYP2D6OPRM1 | |
| SCHEMBL27194844 | 0.86 | CACNA1G (0.69) | CACNA1GCACNA1HCYP3A4CYP2D6OPRM1 | |
| SCHEMBL30849337 | 0.86 | CACNA1G (0.61) | CACNA1GCACNA1HCYP3A4CYP2D6OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1330451-B1 | SUBSTITUTED BENZIMIDAZOL-2-ONES AS VASOPRESSIN RECEPTOR ANTAGONISTS AND NEUROPEPTIDE Y MODULATORS | ORTHO MCNEIL PHARM INC (US) | 2008-01-23 | — | — | EP | disclosed |
| US-6653478-B2 | Psychological disorders; hypotensive agents | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2003-11-25 | — | — | US | disclosed |
| EP-1330451-A2 | SUBSTITUTED BENZIMIDAZOL-2-ONES AS VASOPRESSIN RECEPTOR ANTAGONISTS AND NEUROPEPTIDE Y MODULATORS | Ortho-McNeil Pharmaceutical, Inc. (US) | 2003-07-30 | — | — | EP | disclosed |
| US-20030073842-A1 | Novel substituted benzimidazol-2-ones as vasopressin receptor antagonists and neuropeptide Y modulators | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2003-04-17 | — | — | US | disclosed |
| WO-2002055514-A2 | SUBSTITUTED BENZIMIDAZOL-2-ONES AS VASOPRESSIN RECEPTOR ANTAGONISTS AND NEUROPEPTIDE Y MODULATORS | ORTHO MCNEIL PHARM INC (US) | 2002-07-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073842-A1 | Novel substituted benzimidazol-2-ones as vasopressin receptor antagonists and neuropeptide Y modulators | AVPR2, NPY1R, AVPR1B | CACNA1G 1073/4885CACNA1H 1334/4885CYP3A4 4264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.